INS and deep vein thrombosis: A large phase III clinical trial CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) is currently recruiting participants to assess whether canakinumab may increase insulin secretion and insulin sensitivity in patients with T2DM (ClinicalTrials.gov NCT01327846).